B
Benjamin A. Nacev
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 35
Citations - 1190
Benjamin A. Nacev is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 14, co-authored 26 publications receiving 846 citations. Previous affiliations of Benjamin A. Nacev include Rockefeller University & University of Cincinnati Academic Health Center.
Papers
More filters
Journal ArticleDOI
The expanding landscape of ‘oncohistone’ mutations in human cancers
Benjamin A. Nacev,Benjamin A. Nacev,Lijuan Feng,John D. Bagert,Agata E. Lemiesz,Jianjiong Gao,Alexey A. Soshnev,Ritika Kundra,Nikolaus Schultz,Tom W. Muir,C. David Allis,C. David Allis +11 more
TL;DR: The characterization of missense histone mutations that occur across several cancer types provides insight into the potential role of these mutations in altering chromatin structure and potentially contributing to tumour development.
Journal ArticleDOI
Protein N-terminal processing: substrate specificity of Escherichia coli and human methionine aminopeptidases.
TL;DR: The specificity data have allowed us to formulate a simple set of rules that can reliably predict the N-terminal processing of E. coli and human proteins.
Journal ArticleDOI
Effect of Nitroxoline on Angiogenesis and Growth of Human Bladder Cancer
Joong Sup Shim,Yoshiyuki Matsui,Shridhar Bhat,Benjamin A. Nacev,Jing Xu,Hyo-eun C. Bhang,Surajit Dhara,Kee Chung Han,Curtis R. Chong,Martin G. Pomper,Alan So,Jun O. Liu +11 more
TL;DR: Nitroxoline shows promise as a potential therapeutic antiangiogenic agent and inhibited MetAP2 activity in HUVEC in a dose-dependent manner and induced premature senescence in a biphasic manner.
Journal ArticleDOI
The epigenomics of sarcoma.
Benjamin A. Nacev,Benjamin A. Nacev,Kevin B. Jones,Andrew M. Intlekofer,Jamie S.E. Yu,C. David Allis,William D. Tap,Marc Ladanyi,Torsten O. Nielsen +8 more
TL;DR: How the disease biology of many sarcomas is driven by chromatin pathway alterations ranging from dysregulation of DNA methylation, histone modifications and nucleosome remodelling to disruption of higher-order, 3D chromatin structure is discussed with a view to better develop targeted therapies for patients with sarcoma.
Journal ArticleDOI
The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking and signaling in endothelial cells
TL;DR: It was demonstrated that itraconazole globally reduced poly-N-acetyllactosamine and tetra-antennary complex N-glycans in endothelial cells and induced hypoglycosylation of the epidermal growth factor receptor in a renal cell carcinoma line, suggesting that it raconazoles effects extend beyond VEGFR2.